Mexico / Prospects for Healthcare Ahead of 2024 Election
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
UDIMEB was started back in the 1970s as Proyecto Factor de Transferencia (transfer factor project) by Dr Sergio Estrada-Parra, the father of immunology in Mexico and winner of the National Science Award in 2012, who deepened research on transfer factors to develop an immunomodulatory drug which could be used locally. Today UDIMEB is a three-armed institution which comprises UDIBI, a national laboratory unit offering R&D bioprocess services to the private industry and the academia; USEIC, an institution providing free clinical services in the field of immunology and alternative treatments based on transfer factors to more than 20,000 patients; and FARMA FT, the company in charge of manufacturing the immunomodulatory drug Transferon®.
Contact Details:
UDIMEB
Escuela Nacional de Ciencias Biológicas (ENCB) IPN.
Prolongación de Carpio y Plan de Ayala S/N
Col. Casco de Santo Tomas, Del. Miguel Hidalgo
C.P 11340 MÉXICO DF
MEXICO
Tel: +52 (55) 57296000
Website: http://udibi.com.mx/
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
See our Cookie Privacy Policy Here
